Table 3. The clinicopathologic features according to the status of claudin 18.2 in 81 GC available for Claudin 18.2.
| Variables | Claudin 18.2+ (n=12) | Claudin 18.2− (n=69) | P value |
|---|---|---|---|
| Gender, n (%) | 0.755 | ||
| Male | 8 (66.7) | 41 (59.4) | |
| Female | 4 (33.3) | 28 (40.6) | |
| Age, n (%) | >0.999 | ||
| ≤65 | 9 (75.0) | 51 (73.9) | |
| >65 | 3 (25.0) | 18 (26.1) | |
| Disease extent, n (%) | 0.097 | ||
| Locally advanced disease | 7 (58.5) | 21 (30.4) | |
| Metastatic disease | 5 (41.7) | 48 (69.6) | |
| Tumor site, n (%) | 0.106 | ||
| Cardia | 0 (0.0) | 3 (4.3) | |
| Body | 10 (83.3) | 33 (47.8) | |
| Antrum | 2 (16.7) | 33 (47.8) | |
| Pathologic differentiation, n (%) | 0.886 | ||
| Well | 0 | 0 | |
| Moderate | 4 (33.3) | 23 (33.3) | |
| Poor | 7 (58.7) | 32 (46.4) | |
| Mucinous | 0 (0.0) | 2 (2.9) | |
| Signet ring cell type | 1 (8.3) | 12 (17.4) | |
| Lauren classification, n (%) | 0.026 | ||
| Intestinal type | 4 (33.3) | 20 (29.0) | |
| Diffuse type | 2 (16.7) | 37 (53.6) | |
| Mixed type | 5 (41.7) | 10 (14.5) | |
| NE | 1 (8.3) | 2 (2.9) | |
| HER2 status, n (%) | 0.095 | ||
| Negative | 8 (66.7) | 60 (87.0) | |
| Positive | 4 (33.3) | 9 (13.0) | |
| EBV status (n=75), n (%) | 0.101 | ||
| Negative | 9/12 (75.0) | 59/69 (85.5) | |
| Positive | 3/12 (25.0) | 4/69 (5.8) | |
| NE | 0/12 (0.0) | 6/69 (8.7) |
HER2, human epidermal growth factor receptor 2; EBV, Epstein-Barr virus.